Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for AXITINIB
- Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
- Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
- A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Independent of HER2 Expression With Progression After Previous Treatment
- Phase II Study of Axitinib Intensification Plus Nivolumab Compared to Nivolumab Alone After Induction With Nivolumab Plus Ipilimumab in mRCC Patients Without Previous CR
- A Study of AK104 Plus Axitinib in Advanced/Metastatic Specific Subtypes of Renal Cell Carcinoma
- A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
- Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors
- Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
- Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma
- Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
- Phase I/II Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study
- Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib
- A Study of AK104 Plus Axitinib in Advanced/Metastatic Clear Cell Renal Cell Carcinoma
- Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma
- Avelumab, Palbociclib and Axitinib in Advanced RCC
- A Study on the Safety and Effectiveness of Tislelizumab Combined With Axitinib for Neoadjuvant Treatment of ccRCC
- Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
- Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
- Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
- Axitinib + Ipilimumab in Advanced Melanoma
- Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration
- A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
- TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)
- Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
- Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
- Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- Umbrella Study of Sasanlimab Combined With Targeted Therapies in Participants With Non Small Cell Lung Cancer
- NPC - AXEL Study : Axitinib-Avelumab
- A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
- JS001 Combination Therapy in NSCLC Negative Driving Gene After First-line Chemotherapy.
- Study of PF-07265807 in Participants With Metastatic Solid Tumors.
- Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
- Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma
- Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery
- Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling
- Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
- A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
- Pembrolizumab With Axitinib in Recurrent Endometrial Cancer
- Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma
- Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers
- Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma
- Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma
- Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
- Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
- Phase II Study in the Treatment of Patients With Advanced Mucinous Melanoma
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
- Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy
- A Study of Durvalumab in Combination With Doxorubicin for Advanced Soft Tissue Sarcoma
- A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
- Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib
- Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors
- Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
- Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
- A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
- Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)
- Prior Axitinib as a Determinant of Outcome of Renal Surgery
- Survival Prolongation by Rationale Innovative Genomics
- Testosterone in Metastatic Renal Cell Carcinoma Patients
- Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma
- A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
- Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
- Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
- The Drug Rediscovery Protocol (DRUP Trial)
- Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
- Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14
- Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
- Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14
- Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
- The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
- Expansion Trial for Axitinib In Head And Neck Cancer
- Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
- Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas
- Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)
- Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer
- Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
- SLM + Axitinib for Clear Cell RCC
- A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
- Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma
- Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
- Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
- VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors
- Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea
- A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
- Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
- Second Line Sorafenib After Pazopanib in Patients With RCC
- A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
- Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
- A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
- Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
- Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
- A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
- NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma
- Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
- A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
- Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
- Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib
- Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
- Study of Axitinib and Temsirolimus in Solid Tumors
- Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
- A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
- Assessment of Tumor Vascular Effects of Axitinib With Dynamic Ultrasonography in Patients With Metastatic Colorectal Cancer
- Axitinib as Maintenance Treatment in Patients With Metastatic CRC
- Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
- Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer
- PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma
- A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
- A Study of Axitinib in Advanced Carcinoid Tumors
- Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis
- Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
- Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib
- Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma
- Study of the Combination of Axitinib Plus Everolimus in Patients With Malignant Advanced Solid Tumors
- Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
- Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
- Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)
- Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer
- Nasopharyngeal Carcinoma (NPC) Axitinib
- Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
- Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma
- A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma
- A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
- Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012
- Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer
- Axitinib Pharmacokinetics in Chinese Healthy Volunteers
- A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers
- Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies
- Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer
- Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer
- Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
- Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
- Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer
- Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR]
- Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer
- A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
- Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
- Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
- Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
- AG-013736 In Combination With Gemcitabine Versus Gemcitabine Alone For Patients With Metastatic Pancreatic Cancer
- Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer
- AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
Clinical trials list
click for details